There's Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma

Cureus. 2022 Jan 4;14(1):e20945. doi: 10.7759/cureus.20945. eCollection 2022 Jan.

Abstract

Glaucoma is a common eye disorder and an irreversible cause of blindness worldwide. There are several treatment options for this condition, with the traditional first-line treatment being ophthalmologic drops. Although administered topically, it is associated with inadvertent systemic absorption leading to a potential for both local and systemic side effects. We discuss the case of a 71-year-old male who presented with a complaint of recurring episodes of distressing sensations including lightheadedness, dyspnea, chest pressure, and faintness. His past medical history included congestive heart failure, hypertension, hyperlipidemia, Barrett's esophagus, and glaucoma. Upon a thorough review of the patient's medications, it was discovered that he had recently been started on timolol ophthalmic drops. The patient then noted that his symptoms had begun after he started using the eye drops. After we recommended that the patient hold the use of the eye drops, these episodes stopped. When prescribing topical ophthalmologic drops, providers must educate patients on common systemic side effects of such drugs.

Keywords: beta-blockers; family medicine; glaucoma; internal medicine; ophthalmologic drops; ophthalmology; side effects.

Publication types

  • Case Reports